Provision of Nasal Naloxone
Estimated value
—
Awarded value
—
Suppliers
1
Lots
1
Published
10 Dec 2025
Description
The provision including supply and delivery of nasal Naloxone. Nasal Naloxone supplied must be licensed for use in the UK, compliant with Medicines and Healthcare products Regulatory Agency (MHRA) standards and of a formulation licensed for use on adults and adolescents aged 14 and over. Timely delivery is required to HMPPS settings across England and Wales, including Public Sector (HMPPS) and Privately Managed Prisons, Youth Custody sites, Approved Premises (AP), Independent Approved Premises (IAPs), and Probation Offices and contact centers.
Scope
- Reference
- Prj_14921
- Commercial tool
- Standalone contract
- Contract dates
- 24 Nov 2025 to 23 Nov 2030
- CPV classifications
- 33600000
- Contract locations
- UK, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)Voluntary, community and social enterprises (VCSE)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Technical | Overall Technical Score will be determined by the sum of the weighted scores for the following Technical questions (question weighting in brackets): Service Delivery (40%) Quality Assurance (30%) Contract Performance and Management (20%) Social Value (10%) | quality | — |
| Commercial | — | price | — |
Participation
Conditions suppliers must meet to bid.
As determined in the Project Specific Questionnaire (PSQ) and Instructions to Bidders
Submission & procedure
- Procedure
- Open procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—